Background Early mobilisation after stroke is thought to contribute to the eff ects of stroke-unit care; however, the intervention is poorly defi ned and not underpinned by strong evidence. We aimed to compare the eff ectiveness of frequent, higher dose, very early mobilisation with usual care after stroke.
Introduction
Early mobilisation after stroke, comprising out-of-bed sitting, standing, and walking, is thought to contribute to the powerful eff ect of stroke-unit care 1, 2 and is recommended in many guidelines; however, it is poorly defi ned and not underpinned by strong evidence. 3 The biological rationale underlying the potential for early out-of-bed training centres around three arguments: (1) that bed rest negatively aff ects the musculoskeletal, cardiovascular, respiratory, and immune systems, 4 and might slow recovery; (2) that immobility-related complications are common early after stroke 5 at a time when patients are very inactive; 6 and (3) that there might be a narrow window of opportunity for brain plasticity and repair, 7 and the optimum period for change could be early after stroke. 8 Prompt start and more episodes of out-of-bed activity might therefore improve outcome. However, early mobilisation also has a plausible potential for harm, particularly within the fi rst 24 h of stroke onset. 9 Harms could include damage to the ischaemic penumbra associated with reduced cerebral blood fl ow when the head position is raised, 10 or increased blood pressure associated with activity that might also worsen outcome. 11 Out-of-bed activity could also result in more falls with injury. Concerns about early start of mobilisation appear even more pronounced in the case of intracerebral haemorrhage 9 and in patients with ischaemic stroke treated with thrombolysis. These concerns are largely driven by clinical concerns about the risk of bleeding in the absence of any clear evidence.
This background of clinical uncertainty prompted us to plan and undertake the AVERT trial.
The phase 2 study of AVERT provided preliminary evidence that very early mobilisation started within 24 h of stroke onset and continued frequently thereafter was feasible, likely to be safe 12 with promising improvements in walking recovery, 13 and could be cost eff ective. 14 In 2009, AVERT phase 2 was the only completed mobilisation trial in which intervention started within 48 h of stroke onset. 15 We did the present study to investigate the relative effi cacy of a protocol intended to start earlier than usual care, with frequent out-of-bed activity (very early mobilisation), compared with usual care, traditionally started later (>24 h), with less frequent and lower intensity out-of-bed activity. Our clinical hypotheses were that more intensive, early out-of-bed activity would improve functional outcome at 3 months, reduce immobilityrelated complications, and accelerate walking recovery with no increase in neurological complications. We also postulated that very early mobilisation would result in an improvement in quality of life at 12 months and would be cost eff ective. We aimed to undertake this large, pragmatic trial in a range of stroke units-small and large, urban and regional-with existing clinical staff as the intervention teams. We wanted to recruit a broad sample of patients, including those with intracerebral haemorrhage and those receiving recombinant tissue plasminogen activator, to increase external validity and clinical relevance.
Methods

Study design and participants
We did this pragmatic, parallel-group, single-blind, multicentre, international, randomised controlled trial at 56 stroke units in fi ve countries: Australia, New Zealand, Malaysia, Singapore, and the UK (England, Scotland, Northern Ireland, and Wales). Full details of the study rationale, design, and statistical analysis have been published elsewhere. 16 Eligible patients were aged 18 years or older, had confi rmed fi rst (or recurrent) stroke (infarct or intracerebral haemorrhage), and were admitted to a stroke unit within 24 h of stroke onset. Treatment with recombinant tissue plasminogen activator was allowed. Exclusion criteria were clinically signifi cant pre-morbid levels of disability (modifi ed Rankin Scale score >2), early deterioration, direct admission to the intensivecare unit, documented palliative treatment, immediate surgery, another serious medical illness or unstable coronary condition, no response to voice, systolic blood pressure lower than 110 mm Hg or higher than 220 mm Hg, oxygen saturation lower than 92% with
Research in context
Evidence before this study Early mobilisation after stroke is recommended in many clinical practice guidelines worldwide. In our 2015 review of 30 guidelines, early mobilisation was recommended in 22 examples, but the timing and prescription of the mobilisation intervention is scarcely specifi ed. Early mobilisation is most often recommended as a method to reduce the risk of post-stroke complications, with subsequent improvements in favourable outcome expected. Our early Cochrane review identifi ed no evidence of benefi t, but included only one small randomised controlled trial (AVERT phase 2, n=71). A systematic review and meta-analysis by Lynch and colleagues identifi ed three randomised controlled trials (n=159) in which a protocol of mobilisation starting within 24 h of stroke was compared with usual care. In this review, the investigators reported improved, albeit non-signifi cant, odds of a favourable outcome with early mobilisation (Barthel index odds ratio [OR] 1·20, 95% CI -0·77 to 3·18; p=0·23; OR 1·16, 95% CI 0·61-2·18; p=0·66, with signifi cant heterogeneity I²=66%). The odds of having no complications in the fi rst 3 months after stroke did not diff er signifi cantly between groups (OR 0·92, 95% CI 0·46-1·87, p=0·82). Fewer patients had died by 3 months after stroke in the usual care group (n=6) than in the early mobilisation group (n=15; OR 2·58, 95% CI 0·98-6·79; p=0·06), but this fi nding was not signifi cant. When data on deaths from this meta-analysis are combined with data from the present trial, with both fi xed-eff ects and random-eff ects meta-analysis, the fi ndings are not appreciably changed (fi xed-eff ects OR 1·35, 95% CI 0·99-1·83; p=0.06; random-eff ects OR 1·61, 0·82-3·14; p=0·17, I²=26%). This meta-analysis represents the most recent systematic review of the topic.
Added value of this study
Before AVERT, evidence in trials came from three studies including 159 patients. We now have more robust evidence to inform practice. We believe that the results of AVERT are very generalisable. We have also shown that large, international, high-quality trials of complex interventions in stroke care, trials that are led by physiotherapists and nurses, are possible.
Interpretation
Very early mobilisation was associated with a signifi cant reduction in the odds of little or no disability at 3 months after stroke, with no evidence of accelerated walking recovery; however, the number of patients who died or had serious adverse events at 3 months after stroke did not diff er signifi cantly between groups. Our data show that an early, lower dose out-of-bed activity regimen is preferable to very early, frequent, higher dose intervention, but clinical recommendations should be informed by the future prespecifi ed, detailed analysis of the dose-response association.
oxygen supplementation, resting heart rate of less than 40 beats per min or more than 110 beats per min, temperature greater than 38·5°C, or enrolment in another intervention trial. Patients with subarachnoid haemorrhage were not eligible for the trial.
Institutional review boards at all sites approved the study. Eligible patients were invited to participate in a trial testing "diff erent types of rehabilitation", but were given no specifi c information about the two approaches. 16 Informed consent was obtained from all patients or their nominated representative.
Randomisation and masking
Patients were randomly assigned (1:1), with a secure, remote, web-based computer-generated block randomisation procedure (block size of six), to receive usual stroke-unit care alone or very early mobilisation in addition to usual care. Randomisation was stratifi ed by study site and stroke severity on the basis of baseline National Institutes of Health Stroke Scale (NIHSS) score: mild (NIHSS 1-7), moderate (8) (9) (10) (11) (12) (13) (14) (15) (16) , and severe (>16). 17 Intervention staff were masked to treatment allocation. To reduce the risk of contamination of usual care intervention, staff were trained to conceal the mobilisation protocol and group allocation, patients were unaware of their treatment group, and outcome assessors and investigators involved in trial and data management were masked to group assignment.
Procedures
Components of usual care, including physical therapies, were at the discretion of individual sites. The very early mobilisation intervention included three crucial elements: (1) begin within 24 h of stroke onset; (2) focus on sitting, standing, and walking (ie, out-of-bed) activity; and (3) result in at least three additional out-of-bed sessions to usual care. Patients assigned to very early mobilisation were assisted by physiotherapy and nursing staff trained in study procedures to continue out-of-bed activity at a dose guided by a detailed intervention protocol. The task-specifi c intervention targeted recovery of standing and walking. Functional ability dictated intervention dose, with four levels specifi ed, and dose was adjusted in line with recovery (titrated). We applied a strict protocol in the case of a patient's fi rst time out of bed, with mobilisation out of bed only if the patient's blood pressure did not drop by more than 30 mm Hg on achievement of an upright position. The intervention period lasted 14 days or until discharge from stroke-unit care, whichever was sooner. Therapy and nursing input in both groups was recorded online. Very early mobilisation interventions were not recorded in medical records. Throughout the trial, intervention staff received feedback from an external monitor about intervention compliance per patient, and received quarterly compliance summaries. These summaries were reviewed regularly by the Data Safety and Monitoring Committee.
Outcomes
The primary outcome was a favourable outcome at 3 months after stroke, measured with the modifi ed Rankin Scale. 18 The modifi ed Rankin Scale is an ordinal scale ranging from 0 (no disability) to 5 (severe disability), with a score of 6 allocated to those who die. We defi ned a favourable outcome as modifi ed Rankin Scale scores of 0-2 (no or minimum disability) and a poor outcome as scores of 3-6 (moderate or severe disability, or death).
Major secondary outcomes included an assumptionfree ordinal shift 19, 20 of the modifi ed Rankin score across the entire range of the scale; time taken to achieve unassisted walking over 50 m and the proportion of patients achieving unassisted walking by 3 months; and deaths and the number of non-fatal serious adverse events at 3 months. All serious adverse events were reported according to standard defi nitions. Important medical events were events most relevant to the time period (acute stroke) and intervention, and included stroke progression, recurrent strokes, falls, angina, myocardial infarctions, deep-vein thromboses, pulmonary emboli, pressure sores, chest infections, urinary tract infections, and depression. All deaths and serious adverse events were independently adjudicated by an outcome committee masked to treatment allocation, including a review of source data when necessary. We classifi ed complications as immobility related or neurological, and examined each class of complication separately. Serious complications were categorised into immobility related (pulmonary embolism, deep-vein thrombosis, urinary tract infection, pressure sores, and pneumonia) or neurological (stroke progression and recurrent stroke). Assessments were done in person or, if necessary, by telephone by a trained assessor remote from the hospital ward and masked to treatment allocation. Because very early mobilisation was a complex intervention, we prespecifi ed exploration of dose and subgroup analyses for age, stroke severity, stroke subtype (infarct or haemorrhage), treatment with recombinant tissue plasminogen activator, and time to mobilisation on 3 month outcome.
Statistical analysis
We powered the study to detect an absolute risk reduction of a poor outcome of 7·1% or greater, on the basis of two rationales: (1) consensus among investigators and international advisers that an absolute risk reduction of this magnitude would represent a clinically meaningful eff ect size; and (2) 3 month data for death and institutionalisation from a hospital that has practised early mobilisation for many years showing 9·1% better outcome than in a similar Australian dataset, with early mobilisation estimated to account for 78% of the benefi t, 1 giving a fi nal absolute diff erence of 7·1%. A sample of 2104 patients (1052 per group) was estimated to provide 80% power to detect a signifi cant intervention eff ect (two sided, p=0·05) with adjustments for 5% drop-in and 10% drop-out. We prespecifi ed our statistical analysis plan 16 and used STATA IC (version 13) for all analyses. We did primary effi cacy analysis on an intention-to-treat basis, with an assumption for the main analysis that data were missing at random. 21 We explored the sensitivity of the results to plausible departures from the missing-at-random assumption as part of our intention-to-treat analysis, with use of both a selection model (modelling of the missing data mechanism) and a pattern mixture model (modelling of the diff erences between missing and observed data). Assumptions about the missing data were expressed via a parameter that measures the degree of departure from the missing-at-random assumption. The results were graphed over a range of assumptions (appendix). We did the primary effi cacy analysis with the binary logistic regression model, with treatment group as an independent variable and the 3 month modifi ed Rankin Scale outcome (dichotomised into scores of 0-2 as favourable outcome, and scores of 3-6 as poor outcome) as the dependent variable, including baseline stroke Data are median (IQR) or median (IQR; n), unless otherwise indicated. Dose data for very early mobilisation includes components of both usual care and very early mobilisation. Frequency is derived from nursing and therapist data. Amount (min) is derived from physiotherapist data only. Median estimates include days when time or number of out-of-bed sessions were zero-ie, the patient was recorded as not getting up on that day or for that session. *12 patients were missing from the very early mobilisation group and 14 patients were missing from the usual care group. Missing patients were never mobilised, either because of an early serious adverse event, decision to palliate, or early death or transfer from the stroke unit. For these patients, therapy and nurse recording forms were completed throughout their stroke-unit stay, with zero time and zero sessions. †Daily sessions of out-of-bed activity. ‡Min per day spent in out-of-bed activity. §Total amount is over the length of stay or until 14 days after stroke (whichever took place fi rst). Data are n (%) or median (IQR; n), unless otherwise indicated. All analyses are adjusted for baseline National Institutes of Health Stroke Scale score and age. OR=odds ratio. HR=hazard ratio. mRS=modifi ed Rankin Scale. *16 patients were missing from the very early mobilisation group and fi ve patients were missing from the usual care group. These 21 patients declined follow-up or could not be found. Missing data were analysed according to our intention-to-treat strategy assuming missing at random. The appendix shows results of the sensitivity analysis. †Point estimates are ORs for the primary outcome, generalised ORs for the secondary outcome of mRS category, and HRs for the secondary outcome of walking unassisted. ‡mRS 0-2. §Time at which 50% of participants walked. The number walking unassisted includes all patients who were recorded as having walked 50 m unassisted in the fi rst 3 months. This number might include patients for whom we were unable to obtain 3 month mRS. We estimated the treatment eff ect for ordinal analysis of the modifi ed Rankin Scale (across the full scale) at 3 months with the assumption-free Wilcoxon-MannWhitney generalised odds ratio approach, 19, 20 providing a measure of eff ect size with confi dence intervals. The analysis was again stratifi ed by age and stroke severity.
To examine time taken to achieve unassisted walking 50 m within the fi rst 3 months of stroke, we used a Cox regression model with treatment group as the independent variable, the time to unassisted walking (censored at 3 months) as the dependent variable, and baseline NIHSS and age as treatment covariates. We present the estimated eff ect size as a hazard ratio (HR) with corresponding 95% CI. We analysed walking status (yes or no) with a binary logistic model, with treatment group as the independent variable and walking status as the dependent variable.
We analysed mortality outcomes with the binary logistic regression model, with treatment group as the independent variable and death at 3 months (modifi ed Rankin Scale score of 6) as the dependent variable, and stroke severity and age as treatment covariates. We used negative binomial regression to compare the expected counts of serious complications between groups at 3 months. We report the estimated eff ect sizes and corresponding 95% CI as incidence rate ratios adjusted for age and stroke severity.
To determine whether practice shifted over the course of this trial, we tested the association between the treatment eff ect and the time since the beginning of the trial by inclusion of an appropriate interaction term into the logistic regression model used for the primary outcome analysis. To further examine the possible eff ects of time on the intervention delivered, we did an exploratory analysis in which we examined the eff ect of time since the beginning of the trial on diff erences in individual dose characteristics between the two groups with appropriate regression models (ie, a median regression model for time to fi rst mobilisation and median session frequency, and negative binomial regression for median daily minutes per session and total min over the intervention period) with an interaction term for treatment by time since the trial began.
This trial was registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12606000185561 and the protocol is available online. Data are n/N (%) or n (%), unless otherwise indicated. We did IRR analysis with event counts per person. All analyses are adjusted for age and baseline National Institutes of Health Stroke Scale score. OR=odds ratio. IRR=incidence rate ratio. *Point estimates are OR for death and IRRs for all adverse events. †The 3 month outcome was missing (unknown) for six patients in the very early mobilisation group. Missing data were analysed according to our intention-to-treat strategy assuming missing at random. The results remain stable over the range of possible violations of this assumption. ‡Immobility-related and neurological serious adverse events include both fatal and non-fatal complications; immobility-related events include pulmonary embolism, deep-vein thrombosis, urinary tract infection, pressure sores, pneumonia; and neurological events include stroke progression and recurrent stroke. 
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and, with support of the management committee, had fi nal responsibility for the decision to submit for publication. Figure 1 shows the trial profi le. Between July 18, 2006, and Oct 16, 2014, we randomly assigned 2104 patients to receive either very early mobilisation (n=1054) or usual care (n=1050), with 2083 (99%) patients included in the 3 month follow-up assessment (fi gure 1). Baseline characteristics were similar between study groups (table 1) . Median time to randomisation was 18 h after stroke in both groups (table 1) . For more than 80% of patients, this stroke was their fi rst; 45% of patients were classifi ed as having moderate to severe stroke (NIHSS >7) at time of recruitment, 26% of all patients were older than 80 years, and 24% of patients had received recombinant tissue plasminogen activator (table 1) . The three crucial elements of the very early mobilisation protocol were achieved (table 2). Patients in the very early mobilisation group began mobilising soon after randomisation, at a median of 18·5 h after stroke (table 2) . The median time to mobilisation in the usual care group was also within 24 h of stroke onset, but the median diff erence was almost 5 h later than in patients in the very early mobilisation group (table 2). In the very early mobilisation group, 241 (23%) patients had mobilised within 12 h of stroke, 965 (92%) patients had mobilised within 24 h, and 1038 (98%) patients had mobilised within 48 h; the corresponding numbers in the usual care group were 148 (14%), 623 (59%), and 977 (93%) patients, respectively. Patients in the very early mobilisation group received more frequent out-of-bed sessions than did those in the usual care group (table 2) . The median time to fi rst mobilisation in the usual care group reduced by 28 min per year (95% CI 11·3-44·6, p=0·001) over the study period, with no signifi cant change in the very early mobilisation group. This fi nding resulted in a signifi cant interaction between time since the beginning of the trial and time to fi rst mobilisation (p=0·017). We detected no signifi cant change in either the daily frequency or daily minutes of out-of-bed intervention, or total intervention time, in either group over the study period (data not shown).
Results
More patients in the usual care group than in the very early mobilisation group had a favourable outcome at 3 months after stroke (table 3) , resulting in a signifi cant diff erence between the groups in the analyses adjusted for baseline age and NIHSS (table 3, fi gure 2). We noted similar results in sensitivity analyses (appendix). This treatment eff ect showed no interaction with time since the start of the trial (data not shown). The assumptionfree ordinal analysis did not show a signifi cant diff erence between groups across the entire modifi ed Rankin Scale (scores 0-6).
50% of patients were able to walk unassisted by roughly 7 days after stroke, and 75% were walking by 3 months (n=796 in the usual care group and n=784 in the very early mobilisation group; adjusted OR 0·83, 95% CI 0·64-1·07; p=0·143). Time to walking unassisted did not diff er signifi cantly between groups (table 3, fi gure 3); however, the proportional hazards assumption was violated.
The overall case fatality by 3 months was 8% (95% CI 6·5-8·8). 72 (7%) patients died in the usual care group and 88 (8%) patients died in the very early mobilisation group (table 4). The main causes of death, accounting for 64% of all deaths, were stroke progression (n=19 in the usual care group vs n=31 in the very early mobilisation group), pneumonia (n=15 vs n=19), and recurrent stroke (n=7 vs n=11). Most patients did not have a serious adverse event in the fi rst 3 months (table 4). The proportion of patients who had non-fatal serious adverse events did not diff er signifi cantly between groups (table 4). When complications were examined by prespecifi ed category (immobility vs neurological), fewer than 6% of patients in either group had a fatal or non-fatal serious complication related to immobility (table 4). Fewer than 12% of patients in either group had a serious neurological complication (table 4) , with no signifi cant between-group diff erences. Stroke progression was the most common serious neurological complication, recorded in 128 (6%) patients (n=56 in the usual care group vs n=72 in the very early mobilisation group). Only one staff injury was reported in the very early mobilisation group.
In the prespecifi ed subgroup analyses we noted a more favourable outcome for the usual care intervention than for the very early mobilisation intervention (fi gure 4). The point estimate showed a stronger eff ect in patients with severe stroke and with intracerebral haemorrhage (estimated with lower precision). However, within each individual subgroup analysis, no signifi cant interactions were recorded (all p>0·05; fi gure 4). The appendix shows dose characteristics by subgroup and the subgroup analysis for death at 3 months. Although the eff ect of very early mobilisation on patients with intracerebral haemorrhage seemed to be strong, again, no signifi cant interactions were recorded in this analysis (all p>0·05; appendix).
The median length of hospital stay for acute care and rehabilitation was 16 days (IQR 5-44) for patients in the very early mobilisation group and 18 days (6-43) for those in the usual care group. The number of patients moving on to inpatient rehabilitation was 492 (46%) in the very early mobilisation group and 523 (49%) in the usual care group. Median length of stay for acute care alone was 7 days (IQR 4-13) for patients receiving very early mobilisation and 7 days (4-13) for those receiving usual care; the corresponding times for rehabilitation length of stay were 28 days (15-49) and 30 days (16-51), respectively.
Discussion
Our very early mobilisation protocol was eff ectively delivered, leading to an earlier, more frequent, and higher dose of out-of-bed sitting, standing, and walking activity than usual care. The very early mobilisation intervention signifi cantly reduced the odds of a favourable outcome 3 months after stroke compared with lower dose usual care starting, on average, 5 h later. This outcome of very early mobilisation was recorded against a background of favourable overall prognosis, with almost 50% of patients having a favourable outcome and fewer than 8% dying at 3 months, despite more than 25% of participants being older than 80 years, and more than 45% having had a moderate or severe stroke. Although the case-fatality rate at 3 months was higher in the very early mobilisation group, no signifi cant diff erence was recorded between groups. The prespecifi ed subgroup analyses of effi cacy might provide a signal that patients with severe stroke and those with intracerebral haemorrhage had reduced odds of a favourable outcome by 3 months if treated with the very early mobilisation protocol. Additional exploration of death in the subgroups also suggested that patients with intracerebral haemorrhage might be more susceptible to harm. However, these groups were small with wide confi dence intervals. Although biologically plausible explanations could be made about the diff erential eff ect of a more frequent, higher dose intervention on the odds of a favourable or unfavourable outcome in these subgroups, there was no evidence of any interaction and the results should be interpreted with caution. This study was not powered to detect diff erences between these subgroups; however, such signals of potential harm could be clinically important and warrant further exploration. We also noted that outcomes for patients receiving recombinant tissue plasminogen activator were no diff erent to outcomes for those who did not receive that treatment. Hence, there is no evidence that early mobilisation in this subgroup is harmful.
We were intrigued by these results, partly because our pilot work suggested that the early, frequent, higher dose very early mobilisation protocol increased the odds of a favourable outcome (OR 4·1, 95% CI 0·99-16·89; p=0·05), 12 as did an individual patient meta-analysis, which included two small early mobilisation trials. 22 Conversely, another small trial comparing very early (<24 h) versus later (>24 h) mobilisation, with an unspecifi ed training dose, reported higher, but nonsignifi cant odds, of an unfavourable outcome in the earlier mobilised group. 23 Because the AVERT trial is more than ten times the size of the total sample of all previous mobilisation trials, we believe that our results add precision. The low rates of adverse events overall and, in particular, the low proportion of immobilityrelated complications in both groups was surprising. Our clinical hypothesis was that very early mobilisation would lead to fewer immobility-related complications, but we noted no diff erence between groups. The shift in practice over time to earlier onset intervention in usual care (a median 28 min earlier each year) might explain this result. One of the striking diff erences between previous studies and the present trial is that median time to fi rst mobilisation in usual care has decreased from more than 30 h, 22 to 22 h in this trial. Only 7% of patients in our usual care group stayed in bed for more than 48 h after stroke onset. Unfortunately, no directly comparable data are available from other acute stroke trials. AVERT is the fi rst large rehabilitation trial recruiting patients within 24 h of stroke onset, and although the inclusion criteria were broad, the included patients were a selected population. Modern, high quality stroke-unit care in the participating hospitals, which did include out-of-bed mobilisation within 24 h of stroke onset in 75% of cases, could explain the low rate of immobility-related complications.
This study represents the largest acute stroke rehabilitation trial ever done with a complex intervention directed by existing physiotherapy and nursing staff . We aimed to design and undertake a trial that met the same quality standards expected of drug or device trials, so that eff ect sizes could be sensibly compared. We have achieved this aim, with fewer than 1% of patients missing from the primary endpoint calculation, proven delivery of the intervention protocol, careful characterisation of usual care and adjudicated safety outcomes, and provision of precise estimates of the effi cacy and safety of the intervention. The external validity of the trial has been enhanced by embedding it fully within routine hospital care across fi ve countries. In view of these design considerations, we believe that these results are robust and provide clinicians with important new evidence.
Our trial has several limitations. A consequence of doing large trials is the small amount of information that can be obtained about potential confounding factors (such as physiological variables), and about each staffpatient interaction. This limitation will restrict, but not prevent, further detailed analyses of the eff ect of patient and practice variables on outcome. Being a pragmatic trial, we were not prescriptive about usual care mobilisation practices, which changed signifi cantly during the trial. Independent monitoring, reporting, and feedback about usual care and very early mobilisation did not prevent change in usual care. Usual care clinicians started mobilisation earlier each year, with the result that roughly 60% of patients receiving usual care had started out-of-bed therapy within 24 h of stroke onset. Whether this result was a consequence of contamination from the trial protocol, a response to changes in attitudes to early mobilisation over time as refl ected in recent clinical guidelines, or both, is uncertain.
The results of our trial should aff ect clinical practice by changing present clinical practice guidelines. In our review of 30 guidelines, early mobilisation was recommended in 22 examples, 3 but with little, or more often no, information about the protocol that should be used. The obvious implication of our results is that start of a high-dose, frequent mobilisation protocol within 24 h of stroke onset is not better than usual care. However, because the usual care protocol also represents a complex intervention package that in most cases started early, to advise that patients are provided with usual care is too simplistic. Components of our intervention are already part of routine clinical care; therefore, understanding of which components might aff ect outcome is a priority. By further exploration of this rich dataset, our trial provides the best opportunity yet to develop evidence-based guidelines for patients with stroke about the timing, frequency, and amount of out-of-bed activity to improve outcome (or prevent harm). Consequently, as outlined in our published statistical analysis plan, 16 our next priority will be to undertake a dose-response analysis to establish the eff ect of dose of rehabilitation (rather than group) on effi cacy and safety outcomes.
The results of AVERT raise several important research questions. First, when is the best time to start rehabilitation after stroke? Whereas some early studies in stroke-aff ected rodents suggested that early, intensive exercise increased lesion volume, more recent systematic reviews and meta-analyses have shown a strong positive eff ect for exercise after stroke, including a positive association between better outcome and reduced time to starting exercise. 24, 25 An improved understanding is needed of the molecular mechanisms induced by early physical activity on ischaemic tissue to provide a biological rationale for choice of time windows for intervention. Indeed, this question remains one of the most important questions for the entire timescale after stroke. Second, what should training consist of, and who should we target early? We have shown that the common adage of more is better does not apply to the early post-stroke period. Furthermore, our data signal that some patients might respond better to more conservative treatment protocols. A deep understanding of who responds to treatment, who does not, and why, is missing in the specialty of rehabilitation and should be a research priority.
